Jakarta: In giving vaccine for covid-19, there are a few things to note. Especially the pre-existing conditions.
And, regarding the case of blood clots in vaccines AstraZeneca, it should also be known, can people who already have a history of blood clotting use the AstraZeneca vaccine?
“Actually there is no evidence that people with a history of blood clots (deep vein thrombosis, stroke, ischemic heart) are at risk of developing blood clots due to vaccines. Those who are more at risk are those who have experienced heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2),” said Prof. Zullies Ikawati, PhD. Apt, Professor of the Faculty of Pharmacy UGM, in a release sent by the Indonesian Doctors Association (IDI).
Prof. Zullies said that this incident was very rare. However, he recommends being careful. It is better for those who have a history of blood clots not to use this type of vaccine.
Prof. Zullies also explained that the exact mechanism that causes blood clotting by the AstraZeneca vaccine is still being studied. But a German researcher, Greinacher, suspects that this rare blood-clotting reaction is related to his vaccine platform, a viral vector using an adenovirus.
“It’s not certain yet, but previous studies using the adenovirus platform turned out to produce the same reaction, namely platelet activation which causes blood clotting,” said Prof. Zullies.
“And the same reaction was also found in the use of the Johnson and Johnson vaccine which uses the same platform, namely adenovirus. The use of the Johnson & Johnson vaccine was stopped in America and after being evaluated it can be reused,” continued Prof. Zullies.
The incidence of blood clots due to the use of the AstraZeneca vaccine, according to Prof. Zullies, it’s very rare. As of May 5, 2021, in Europe there have been reports of 262 cases of blood clots due to this vaccine.
“With 51 of them died, from the use of as many as 30 million doses of vaccine. If it is calculated, the percentage of occurrence is very small,” said Prof. Zullies.
“That’s why the European Medicines Agency (EMA), still considers that even if this vaccine can cause a blood clotting reaction, the benefits still outweigh the risks, so this vaccine can still be given,” concluded Prof. Zullies.
(FIR)
– .
